Effect of Immune-enhancing Enteral Nutrition on Immunomodulation in Critically Ill Patients
- Conditions
- Critical Illness
- Registration Number
- NCT02569203
- Lead Sponsor
- Yonsei University
- Brief Summary
To determine whether high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients (eg, ω-3 fatty acids and antioxidants) enriched with β-glucan stimulates immune functions compared with standard enteral nutrition (control: 20% of total calorie from protein) or high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients without β-glucan in critically ill patients.
- Detailed Description
To determine whether high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients (eg, ω-3 fatty acids and antioxidants) enriched with β-glucan stimulates immune functions compared with standard enteral nutrition (control: 20% of total calorie from protein) or high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients without β-glucan in critically ill patients. In a randomized double-blind placebo-controlled study, 30 patients consumed 1 of 3 enteral nutrition: control, enteral nutrition of immune modulating nutrients enriched with β-glucan (250mg/L) or enteral nutrition of immune modulating nutrients without β-glucan. Enteral nutrition was initiated within 24 hours of ICU admission and continued during the ICU stay for a 7 days.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
- ICU patients
- ICU patients who could not receiving enteral nutrition
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline NK cell activity at 7 days at baseline and 7 days follow-up NK cell activity (%)
- Secondary Outcome Measures
Name Time Method Change from baseline IL-12 at 7 days at baseline and 7 days follow-up IL-12 (pg/mL)
Change from baseline hs-CRP at 7 days at baseline and 7 days follow-up hs-CRP (mg/dL)